TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04895137
Drug: mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
Study: NCT06109311
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06626711
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol as a part of total venous anesthesia
Study: NCT06626711
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane as a part of intravenous anesthesia
Study: NCT06690814
Drug: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
Normalized name: Listerine Antiseptic
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Common over the counter antiseptic cream
Study: NCT05907395
Drug: PF-07293893
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
Study: NCT06071767
Drug: Vesatolimod (VES)
Normalized name: colloidal oatmeal
DrugBank: Vesatolimod (DB12687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
Study: NCT06071767
Drug: GS-5423
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via intravenous (IV) infusion at week 7
Study: NCT06071767
Drug: GS-2872
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via IV infusion at week 7
Study: NCT05334368
Drug: Depemokimab
Normalized name: Depemokimab
DrugBank: Depemokimab (DB18846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depemokimab will be administered.
Study: NCT06708741
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin D supplementation (50,000 IU/once per month)
Study: NCT06709313
Drug: Chromium
Normalized name: Chromium
DrugBank: Chromium (DB11136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
Study: NCT06708858
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg，qd，po
Study: NCT06708858
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/ m2, IV，d1，8，q3w
Study: NCT06708858
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2，IV，d1，8，q3w
Study: NCT06708858
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg，IV，d1，q3w
Study: NCT06708858
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg，IV，d1，q3w
Study: NCT06710158
Drug: SC-102
Normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.
Study: NCT05843838
Drug: Heavy Bupivacaine for spinal anesthesia
Normalized name: bupivacaine hydrochloride Injectable Solution [Marcain Heavy]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine clinical heavy bupivacaine doses
Study: NCT05442190
Drug: Hypericin
Normalized name: Hypericin
DrugBank: Hypericin (DB13014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Study: NCT05502341
Drug: Bictegravir
Normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally without regard to food
Study: NCT05502341
Drug: Lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT05730777
Drug: Bifidobacterium Bifidum Oral Capsule
Normalized name: Bifidobacterium Bifidum Oral Capsule
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
Study: NCT05730777
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT05730777
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT05957367
Drug: Ripretinib
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Tablet Formulation
Study: NCT05730777
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT05730777
Drug: Atlizumab
Normalized name: Atlizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Study: NCT06199037
Drug: SHR-1707
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
Study: NCT04797000
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Study: NCT04493333
Drug: Vaginal Dehydroepiandrosterone
Normalized name: DEHYDROEPIANDROSTERONE
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
Study: NCT06431373
Drug: Brepocitinib PO QD
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib PO QD
Study: NCT04713657
Drug: Propranolol Hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
Study: NCT05624359
Drug: FA plus ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
Study: NCT05624359
Drug: ropivacaine alone
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
Study: NCT04868409
Drug: Suxamethonium
Normalized name: Suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg for tracheal intubation after 60 seconds
Study: NCT04868409
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg for tracheal intubation after 60 seconds
Study: NCT00939705
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study: NCT04234191
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
Study: NCT04234191
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
Study: NCT05011305
Drug: Saroglitazar Magnesium 2 mg
Normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Study: NCT05011305
Drug: Saroglitazar Magnesium 4 mg
Normalized name: pitavastatin magnesium 4 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
Study: NCT05108922
Drug: Donanemab
Normalized name: Donanemab
DrugBank: Donanemab (DB16647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
Study: NCT05108922
Drug: Aducanumab
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Study: NCT06531291
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg, po, qd, q3w
Study: NCT06531291
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, iv, d1, q3w
Study: NCT05443061
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
Study: NCT06143553
Drug: Paclitaxel Polymeric Micelles for Injection
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
Study: NCT06143553
Drug: Eribulin Mesilate injection
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
Study: NCT04934514
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 intravenous infusion
Study: NCT04934514
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 intravenous infusion
Study: NCT06143553
Drug: Gemcitabine Hydrochloride for Injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
Study: NCT06143553
Drug: Vinorelbine Tartrate Injection
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
Study: NCT06143553
Drug: Paclitaxel (albumin-bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
Study: NCT06365216
Drug: NX210c
DrugBank: NX-210c (DB18209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a week, for 4 weeks
Study: NCT05831891
Drug: Fruquintinib combined with Serplulimab
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
Study: NCT03752203
Drug: Sodium Fluorescein
Normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
Study: NCT05816733
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
Study: NCT06530537
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg twice daily
Study: NCT06530537
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg once daily
Study: NCT06402747
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg once daily
Study: NCT06402747
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200mg per day
Study: NCT04221438
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04912011
Drug: Canrenoate Potassium
Normalized name: canrenoate potassium
DrugBank: Canrenoic acid (DB09015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Study: NCT06083935
Drug: Combined oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
Study: NCT06083935
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucophage ® 500 tablets twice daily
Study: NCT04946461
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
Study: NCT04221438
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05712876
Drug: CK-0045
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-22 agonist
Study: NCT06379087
Drug: Anlotinib Hydrochloride Capsule
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
Study: NCT06379087
Drug: Tislelizumab Injection
Normalized name: tislelizumab Injection
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
Study: NCT04837092
Drug: FR104
Normalized name: Foralumab
DrugBank: Foralumab (DB16170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR104 treatment administration at day 0, day 14 then every 28 days until month 12
Study: NCT06273540
Drug: STP7 (mavoglurant) or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Study: NCT05128929
Drug: Hymecromone (H01)
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral H01 two times a day (total dose: 1600 mg/day).
Study: NCT05255653
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg twice daily for one year
Study: NCT05255653
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
Study: NCT05255653
Drug: Medroxyprogesterone Acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate for two years
Study: NCT05255653
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate for two years
Study: NCT04476550
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
Study: NCT06104644
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
Study: NCT04460937
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06492005
Drug: PD-1 inhibitior
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Study: NCT06136728
Drug: Dalfampridine 10 MG [Ampyra]
Normalized name: dalfampridine 10 MG [Ampyra]
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks.
Study: NCT06047158
Drug: Omega-3 fish oil fat emulsion
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use omega-3 fish oil fat emulsion
Study: NCT05364099
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
Study: NCT06392971
Drug: Deep-sea fish oil
Normalized name: Deep Sea
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
Study: NCT05364099
Drug: Triamcinolone Injection
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
Study: NCT05559554
Drug: AK104 (before the change)
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
Study: NCT04950166
Drug: pegsitacianine
Normalized name: Pegsitacianine
DrugBank: Pegsitacianine (DB19098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).